Literature DB >> 31073023

Metastatic Adrenal Cortical Carcinoma Responding to Octreotide: A Case Report.

Xiang Wang1, Na Zhou1, Yu Xiao2, Wenjia Zhu3, Chunmei Bai1, Lin Zhao4.   

Abstract

Advanced adrenocortical carcinoma (ACC) is an aggressive disease with poor prognosis, and the current therapeutic options, such as mitotane or platinum-based chemotherapy regimens, often offer limited efficacy. Here, we present the first report, to the author's knowledge, of metastatic ACC with positive octreoscan scintigraphy that was successfully treated with octreotide long-acting release (LAR). A patient with metastatic ACC who showed poor tolerance to mitotane received octreotide LAR because of positive octreoscan scintigraphy. She obtained major partial response to the somatostatin analog. Interestingly, the expression of somatostatin receptor 2 from the previous local recurrence lesion was negative. The next-generation sequencing-based circulating tumor DNA analysis in the patient was performed and failed to identify any alterations. These findings suggest that octreotide LAR may be a good option for the treatment of metastatic ACC in selected patients. © AlphaMed Press 2019.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31073023      PMCID: PMC6693704          DOI: 10.1634/theoncologist.2018-0855

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  34 in total

1.  The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.

Authors:  Antonio M Lerario; Francis P Worden; Carole A Ramm; Elizabeth A Hesseltine; Elizabeth A Hasseltine; Walter M Stadler; Tobias Else; Manisha H Shah; Edem Agamah; Krishna Rao; Gary D Hammer
Journal:  Horm Cancer       Date:  2014-05-22       Impact factor: 3.869

Review 2.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

3.  Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.

Authors:  Antonina Germano; Ida Rapa; Eleonora Duregon; Arianna Votta; Jessica Giorcelli; Consuelo Buttigliero; Giorgio V Scagliotti; Marco Volante; Massimo Terzolo; Mauro Papotti
Journal:  Endocr Pathol       Date:  2017-06       Impact factor: 3.943

4.  Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.

Authors:  Evanthia Diakatou; Krystallenia I Alexandraki; Apostolos V Tsolakis; George Kontogeorgos; Eleftherios Chatzellis; Anastasia Leonti; Gregory A Kaltsas
Journal:  Clin Endocrinol (Oxf)       Date:  2015-04-24       Impact factor: 3.478

5.  Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy.

Authors:  Marco Volante; Maria Pia Brizzi; Antongiulio Faggiano; Stefano La Rosa; Ida Rapa; Anna Ferrero; Gelsomina Mansueto; Luisella Righi; Silvana Garancini; Carlo Capella; Gaetano De Rosa; Luigi Dogliotti; Annamaria Colao; Mauro Papotti
Journal:  Mod Pathol       Date:  2007-09-14       Impact factor: 7.842

6.  Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.

Authors:  Sebastian Wortmann; Marcus Quinkler; Christian Ritter; Matthias Kroiss; Sarah Johanssen; Stefanie Hahner; Bruno Allolio; Martin Fassnacht
Journal:  Eur J Endocrinol       Date:  2009-11-10       Impact factor: 6.664

7.  Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.

Authors:  M John; W Meyerhof; D Richter; B Waser; J C Schaer; H Scherübl; J Boese-Landgraf; P Neuhaus; C Ziske; K Mölling; E O Riecken; J C Reubi; B Wiedenmann
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

8.  Integrated genomic characterization of adrenocortical carcinoma.

Authors:  Guillaume Assié; Eric Letouzé; Martin Fassnacht; Anne Jouinot; Windy Luscap; Olivia Barreau; Hanin Omeiri; Stéphanie Rodriguez; Karine Perlemoine; Fernande René-Corail; Nabila Elarouci; Silviu Sbiera; Matthias Kroiss; Bruno Allolio; Jens Waldmann; Marcus Quinkler; Massimo Mannelli; Franco Mantero; Thomas Papathomas; Ronald De Krijger; Antoine Tabarin; Véronique Kerlan; Eric Baudin; Frédérique Tissier; Bertrand Dousset; Lionel Groussin; Laurence Amar; Eric Clauser; Xavier Bertagna; Bruno Ragazzon; Felix Beuschlein; Rossella Libé; Aurélien de Reyniès; Jérôme Bertherat
Journal:  Nat Genet       Date:  2014-04-20       Impact factor: 38.330

9.  Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.

Authors:  Amira Mohamed; Marie-Pierre Blanchard; Manuela Albertelli; Federica Barbieri; Thierry Brue; Patricia Niccoli; Jean-Robert Delpero; Genevieve Monges; Stephane Garcia; Diego Ferone; Tullio Florio; Alain Enjalbert; Vincent Moutardier; Agnes Schonbrunn; Corinne Gerard; Anne Barlier; Alexandru Saveanu
Journal:  Endocr Relat Cancer       Date:  2014-07-10       Impact factor: 5.678

10.  Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.

Authors:  Felix Megerle; Wiebke Herrmann; Wiebke Schloetelburg; Cristina L Ronchi; Alina Pulzer; Marcus Quinkler; Felix Beuschlein; Stefanie Hahner; Matthias Kroiss; Martin Fassnacht
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.